

Claims:

Sub B₁

1. A formulation for transdermal electrotransport delivery, comprising an aqueous solution of a drug or an electrolyte and a dipeptide buffer, the dipeptide buffer comprising a polypeptide chain of 2 to 5 amino acids and having an isoelectric pH at which the dipeptide carries no net charge, the dipeptide having at least 2 pKa's which are separated by no more than about 3.5 pH units, the solution having a pH which is within about 1.0 pH unit of the isoelectric pH.

2. The formulation of claim 1, wherein the isoelectric pH of the dipeptide is between about 3 and 10.

3. The formulation of claim 1, wherein the dipeptide is present in the solution at a concentration of at least about 10 mM.

4. The formulation of claim 1, wherein the dipeptide includes at least one amino acid selected from the group consisting of His, Tyr, Arg, Cys, Lys, Asp and Glu.

5. The formulation of claim 1, wherein the dipeptide includes His.

6. The formulation of claim 1, wherein the dipeptide is Gly-His.

7. The formulation of claim 1, wherein dipeptide is selected from the group consisting of Asp-Asp, Gly-Asp, Asp-His, Glu-His, His-Glu, His-Asp, Glu-Arg, Glu-Lys, Arg-Glu,, Lys-Glu, Arg-Asp, Lys-Asp, His-Gly, His-Ala, His-Asn, His-Citruline, His-Gln, His-Hydroxyproline, His-Isoleucine, His-Leu, His-Met, His-Phe, His-Pro, His-Ser, His-Thr, His-Trp, His-Tyr, His-Val, Asn-His, Thr-His, Try-His, Gin-His, Phe-His, Ser-His, Citruline-His, Trp-His, Met-His, Val-His, His-His, Isoleucine-His, Hydroxyproline-His, Leu-His, Ala-

1 His, Gly-His, Beta-Alanylhistidine, Pro-His, Carnosine, Anserine, Tyr-Arg,
2 Hydroxylysine-His, His-Hydroxytyrosine, Ornithine-His, His-Lys, His-Ornithine
3 and Lys-His.
4

5 8. The formulation of claim 1, wherein the drug comprises a
6 polypeptide or a protein.
7

8 ~~9~~ 9. A transdermal electrotransport drug delivery device having a
9 reservoir containing the formulation of claim 1.
10

11 10. A transdermal electrotransport drug delivery device having
12 a drug-containing donor reservoir containing the formulation of claim 1.
13

14 11. A transdermal electrotransport drug delivery device having a
15 electrolyte-containing counter reservoir containing the formulation of claim 1.
16

17 ~~12~~ 12. A method of buffering an aqueous solution of a drug or an
18 electrolyte used for transdermal electrotransport delivery, comprising buffering
19 the solution with a dipeptide comprising a chain of 2 to 5 amino acids and
20 having an isoelectric pH at which the dipeptide carries no net charge, the
21 dipeptide having at least 2 pKa's which are separated by no more than about
22 3.5 pH units, the solution having a pH which is within about 1.0 pH unit of the
23 isoelectric pH.
24

25 13. The method of claim 12, wherein the isoelectric pH of the
26 dipeptide is between about 3 and 10.
27

28 14. The method of claim 12, wherein the dipeptide is present in
29 the solution at a concentration of at least about 10 mM.
30

0919089 11139

1 15. The method of claim 12, wherein the dipeptide contains one
2 or more of His, Tyr, Arg, Cys, Lys, Asp and Glu.

3
4 16. The method of claim 12, wherein the dipeptide contains His.

5
6 17. The method of claim 12, wherein the dipeptide is Gly-His.

7
8 18. The method of claim 12, wherein dipeptide is selected from
9 the group consisting of Asp-Asp, Gly-Asp, Asp-His, Glu-His, His-Glu, His-Asp,
10 Glu-Arg, Glu-Lys, Arg-Glu,, Lys-Glu, Arg-Asp, Lys-Asp, His-Gly, His-Ala, His-
11 Asn, His-Citruline, His-Gln, His-Hydroxyproline, His-Isoleucine, His-Leu, His-
12 Met, His-Phe, His-Pro, His-Ser, His-Thr, His-Trp, His-Tyr, His-Val, Asn-His,
13 Thr-His, Try-His, Gin-His, Phe-His, Ser-His, Citruline-His, Trp-His, Met-His,
14 Val-His, His-His, Isoleucine-His, Hydroxyproline-His, Leu-His, Ala-His, Gly-
15 His, Beta-Alanylhistidine, Pro-His, Carnosine, Anserine, Tyr-Arg,
16 Hydroxylysine-His, His-Hydroxytylsine, Ornithine-His, His-Lys, His-Ornithine
17 and Lys-His.

18
19 19. The method of claim 12, wherein the drug comprises a
20 polypeptide or a protein.

21
22 LOZ * 20. The method of claim 12, wherein the solution is contained
23 in a reservoir of a transdermal electrotransport drug delivery device.
24
25
26

09190887 11293